Kelly Paul Edward 4
4 · RELMADA THERAPEUTICS, INC. · Filed Apr 5, 2022
Insider Transaction Report
Form 4
Kelly Paul Edward
DirectorChief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2022-04-04$3.24/sh+10,000$32,400→ 197,295 total - Exercise/Conversion
Options to purchase common stock
2022-04-04−10,000→ 20,500 totalExercise: $3.24From: 2017-10-20Exp: 2027-10-20→ Common Stock (10,000 underlying) - Sale
Common Stock
2022-04-04$30.04/sh−10,000$300,395→ 187,295 total
Footnotes (4)
- [F1]The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020.
- [F2]The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- [F3]Sales prices range from $30.00 to $30.20 per share, inclusive.
- [F4]The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period.